# PAS-004 in Patients With Advanced Solid Tumors

> **NCT06299839** · PHASE1 · RECRUITING · sponsor: **Pasithea Therapeutics Corp.** · enrollment: 48 (estimated)

## Conditions studied

- RAS Mutation
- NF1 Mutation
- RAF Mutation
- Advanced Solid Tumors

## Interventions

- **DRUG:** PAS-004 Capsules
- **DRUG:** PAS-004 Tablets

## Key facts

- **NCT ID:** NCT06299839
- **Lead sponsor:** Pasithea Therapeutics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2026-02
- **Final completion:** 2027-02
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299839, "PAS-004 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06299839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*